今日东方甄选股价上演"天地板"，早盘一度暴涨逾23%，午后高台跳水，盘后跌20.89%。有消息称新东 方CEO周成刚或涉关联交易被监管部门立案调查。东方甄选方面向第一财经记者回应称：纯属谣言。 东方甄选方面向第一财经记者回应称：纯属谣言。 ...

智通财经APP讯，兖煤澳大利亚(03668)公布，将于2025年9月19日派发中期股息每股0.316386港元。 ...

智通财经APP讯，汇丰控股(00005)发布公告，于2025年8月18日，该公司斥资2.68亿港元回购270.12万 股。 ...

Market Performance - The Hang Seng Index closed down by 0.21% and the Hang Seng Tech Index fell by 0.67% [1] - Oriental Selection experienced a significant drop, closing down over 20% after reaching a peak increase of 23% during the day [1] Biopharmaceutical Sector - Biopharmaceutical stocks continued to decline, with Gilead Sciences-B dropping over 15%, Peijia Medical-B down over 8%, and Hengrui Medicine falling over 5% [1] Other Notable Stocks - Zhihu saw a notable increase, rising over 23% [1]

浙江零跑科技股份有限公司（简称："零跑汽车"，股票代码："9863"）今日发布截至2025年6月30日的业绩报告，财报显示，零跑汽车2025年上半年营收 为242.49亿元，较上年同期的88.45亿元增长174%。 | | 截至6月30日止六個月 | | | --- | --- | --- | | | 2025年 | 2024年 | | | 人民幣千元 | 人民幣千元 | | | (未經審計) | (未經審計) | | 收益 | 24.249.601 | 8.845.408 | | 销售成本 | (20,823,968) | (8.745.183) | | 毛利 | 3,425,633 | 100,225 | | 銷售開支 | (1.405.355) | (902.653) | | 行政開支 | (789.558) | (435.015) | | 研發開支 | (1.894.331) | (1.221.285) | | 金融資產及合約資產減值虧損淨額 | (3,447) | (354) | | 其他收入 | 510,496 | 42,756 | | 其他收益一淨額 | 67,932 | 21,297 | | ...

对于购买整车的用户，若还未提车，蔚来将按照调整后100kWh长续航电池包价格安排交付；若已提车，在2025年 1月1日至2025年8月18日期间完成交付的用户，蔚来将为其发放价值2万元的焕新礼金券，该礼金券可用于增换购 蔚来品牌全系新车时直接抵减车价。 在电池升级服务方面，永久升级服务定价由5.8万下调至3.8万元；电池灵活升级保持定价不变。 蔚来汽车表示，此次价格调整和升级服务的推出，是为了更好地回馈用户，提升用户体验。 8月19日，蔚来汽车宣布，自即日起，蔚来100kWh长续航电池包价格从12.8万元下调至10.8万元，降幅达15.6%。 （校对/黄仁贵） ...

Core Viewpoint - The stock price of Yuan Da Pharmaceutical (00512) surged over 7% ahead of its earnings announcement, reflecting positive market sentiment following the FDA approval of its radioactive product for treating unresectable hepatocellular carcinoma (HCC) [1] Company Developments - Yuan Da Pharmaceutical plans to hold a board meeting on August 19 to approve its interim results [1] - The company announced that its yttrium-90 microsphere injection has received FDA approval for a new indication, making it the first and only selective internal radiation therapy product approved for both unresectable HCC and colorectal cancer liver metastases [1] - The company has established a complete industrial chain in the nuclear medicine sector, with its core product, Yttrium-90 microsphere injection, rapidly gaining market traction since its domestic approval in 2022 [1] Market Performance - As of the report, Yuan Da Pharmaceutical's stock rose by 6.92%, trading at 8.96 HKD with a transaction volume of 283 million HKD [1] - Tianfeng Securities noted that the product has treated nearly 2,000 patients by the end of 2024, projecting sales revenue of nearly 500 million RMB for that year [1] Future Outlook - The company aims to build a comprehensive layout in tumor interventional therapy and the RDC platform, actively advancing multiple nuclear medicine products in clinical research [1] - The firm is expected to enter an accelerated development phase, supported by its innovative product offerings and market positioning [1]

21世纪经济报道记者高江虹实习生蒋中阳 8月18日，同程旅行（00780.HK）发布的2025年第二季度及上半年财报显示，同程上半年实现营收90.5 亿元，同比增长11.5%，经调整净利润15.6亿元，同比增长28.6%。尽管非一线城市消费潜力的释放推动 了用户规模和客均收入的增长，但与行业龙头携程相比，同程在营收规模、国际化布局和盈利能力上仍 存明显差距，尤其是收入增长放缓的迹象更引发市场对其长期竞争力的关注。 与行业龙头携程和飞猪相比，同程的竞争短板清晰。携程2025年第一季度营收138亿元，同比增长 16%，远高于同程半年90.5亿元的规模，彰显规模优势和增长稳定性。盈利能力方面，携程2024年经调 整EBITDA利润率稳定在32.1%，而同程同期只有23.5%，虽然较2023年提升了0.7%，仍落后携程8.6个 百分点。携程2025年一季度的经调整EBITDA利润率还保持在31%，也高于同程旅行同期的26.5%。 国际化布局是同程的另一短板。携程2024年国际机票和酒店预订收入占比已达30%，出境游业务恢复至 2019年同期的80%以上，2025年第一季度出境游机酒预订量更达疫情前120%。携程在东南 ...

Core Insights - Leap Motor reported a revenue of 24.25 billion yuan for the first half of the year, a 174% increase compared to 8.85 billion yuan in the same period of 2024, and achieved a net profit of 30 million yuan, reversing a loss of 2.21 billion yuan from the previous year, making it the second Chinese new car manufacturer to achieve profitability in the first half of the year [2] - The increase in revenue is attributed to higher vehicle and parts delivery volumes, income from strategic partnerships and carbon credit trading, and increased service revenue driven by vehicle deliveries [2] - The total vehicle delivery volume for the company reached 221,664 units, ranking first among new car manufacturers in China [2] Delivery Performance - In July 2025, the company’s delivery volume reached a new high of 50,129 units, maintaining the top position in the new car manufacturer sales rankings for five consecutive months, and is the only new car manufacturer in China to exceed 50,000 units in monthly deliveries since 2025 [2] Product Development - Since 2025, the company has launched two new models on the B platform and updated three existing models on the C platform, enhancing its product matrix to meet diverse customer needs [2] - All new models are built on the new LEAP 3.5 architecture, providing cutting-edge technology experiences for users [2] - The Leap B10 was launched on April 10, 2025, featuring end-to-end assisted driving capabilities, laser radar, and Qualcomm 8650 chip in a 120,000 yuan SUV [2] R&D Investment - The company has significantly increased its investment in intelligent driving research and development, with the scale of the intelligent driving team and computing resources nearly doubling compared to the same period in 2024 [3] - The city commuting navigation assistance function based on end-to-end algorithms has achieved mass production and is now on vehicles [3] - The development efficiency of the Qualcomm 8650 domain control combination assisted driving solution has improved significantly, completing development and first application on B platform models within six months [3] Future Plans - The company plans to further increase strategic investments in the second half of 2025, enhancing resources for end-to-end and VLA technology research and development, with a goal to achieve city NOA combination assisted driving capabilities by the end of 2025 [3]

Core Viewpoint - *ST Muban (603398.SH) announced that its wholly-owned subsidiary, Guangxi Muban High-tech New Energy Co., Ltd., has received court seizure notices regarding its assets, which have been frozen or are subject to pending seizure, indicating potential financial distress for the company [1] Group 1 - Guangxi Muban's production site, including office and production equipment, as well as related real estate, has been seized by the Wuxi District People's Court in Guangxi Zhuang Autonomous Region [1] - The estimated book value of the seized assets is 98 million yuan, which accounts for 10% of the company's most recent audited net asset total [1]